Cervical Cancer Treatment Market

The cervical cancer treatment market is expected to increase from US$ 10.26 billion in 2024 to US$ 14.91 billion by 2031, with a projected CAGR of 5.7% from 2025 to 2031.

Market Insights and Analyst Perspective:The forecast for the cervical cancer treatment market can assist stakeholders in formulating their growth strategies.

Cervical cancer is defined as cancer that develops in the cervix cells, which is the lower section of the uterus connecting to the vagina. In 90% of cases, cervical cancers are caused by HPV infections and are identified through smear screening. The rising incidence of cervical cancer and the increase in HPV infections are the primary factors propelling the growth of the cervical cancer treatment market. However, the lack of awareness regarding diagnosis and treatment options poses a challenge to market growth. Trends in the cervical cancer treatment market include heightened R&D efforts for cervical cancer diagnostics and therapeutics.

Growth Drivers and Challenges:Rising Incidence of Cervical Cancer Drives Market Growth

Globally, cancer is becoming a leading cause of death. According to the World Health Organization (WHO), cancer was the leading cause of death for individuals under 70 in 183 countries, and the fourth leading cause in 123 other nations in 2019. Additionally, WHO data from March 2021 indicated that nearly 10 million deaths in 2020 were due to various cancers. The cervical cancer treatment market has experienced significant growth, attributed to the increasing incidence of cervical cancer among women worldwide. The WHO reports that cervical cancer claims the lives of over 270,000 women annually, with higher mortality rates in low-income countries due to late-stage diagnosis.

The rising incidence of cervical cancer is placing a strain on healthcare systems globally. The International Agency for Research on Cancer (IARC) estimates that the global burden of new cancer cases will reach approximately 27.5 million, leading to around 163 million deaths by 2040. Factors such as lifestyle changes, smoking, decreased physical activity, and uncertain health and environmental conditions are expected to exacerbate the cancer burden in the coming years. Therefore, it is crucial to control and prevent the rising number of cancer cases worldwide.

Factors contributing to the high incidence and mortality rates of cervical cancer include a lack of awareness among populations, healthcare providers, and policymakers; limited access to quality healthcare services and cervical screening programs; and inadequate referral systems. In developed countries, cervical cancer incidence and mortality have decreased due to improved access to cytological screening and prompt treatment of early cervical lesions. Implementing population-based cervical screening and enhancing its acceptance in low- and middle-income countries (LMICs) is vital for reducing cervical cancer mortality. Increasing awareness of risk factors such as early sexual activity, multiple male sexual partners, the risks associated with HPV types 8, 9, and 10, early full-term pregnancies, prolonged oral contraceptive use, and HIV infections may encourage participation in screening programs. Improved awareness of cervical cancer symptoms, including intermenstrual bleeding, postmenopausal bleeding, post-coital bleeding, foul vaginal discharge, and lower abdominal pain, could prompt women to seek early medical attention. Thus, the lack of awareness about cervical cancer among populations is a significant barrier to the growth of the cervical cancer treatment market.

Strategic Insights

Report Segmentation and Scope:Segmental Analysis:The market is categorized by type into squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma. The squamous cell carcinoma segment held a larger share of the cervical cancer treatment market in 2022 and is expected to exhibit a higher CAGR from 2022 to 2030. By product, the market is divided into surgery, radiation therapy, chemotherapy, immunotherapy, and therapeutic vaccines, with the surgery segment anticipated to maintain a significant share by 2030. In terms of end users, the market is segmented into hospitals, homecare, cancer centers, and others, with hospitals holding the largest share in 2022.

Regional Analysis:The cervical cancer treatment market report covers regions including North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America accounted for the largest share of the cervical cancer treatment market in 2022, with the US holding a significant portion. Ongoing R&D activities, government and private sector financial support, collaborations between IT and pharmaceutical companies, and the rising incidence of neurological diseases are key drivers of market growth in the US. Additionally, government initiatives aimed at improving testing procedures are expected to benefit the market during the forecast period. The increasing adoption of regulations related to rare diseases is likely to create opportunities for market growth, such as the American Cancer Society (ACS) revising cervical cancer screening guidelines in September 2020.

Cervical Cancer Treatment Market Report Scope

Industry Developments and Future Opportunities:The analysis of the cervical cancer treatment market involves identifying and assessing key players in the industry. Some initiatives by major market players include:

In January 2024, Pfizer Inc. and Genmab A/S announced that the US Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) to convert TIVDAK's (tisotumab vedotin-tftv) approval for treating patients with recurrent or metastatic cervical cancer whose disease progresses after first-line therapy. The application has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 9, 2024.

In September 2023, Guangzhou Gloria Biosciences (GloriaBio) announced that Zimberelimab injection (YuTuo, GLS-010), a fully human anti-PD-1 monoclonal antibody, received marketing approval from the China National Medical Products Administration (NMPA). This injection can be used as a monotherapy for patients with recurrent or metastatic cervical cancer (R/M CC), making zimberelimab the third immune checkpoint inhibitor (ICI) antibody approved globally for cervical cancer treatment and the first authorized in China.

Competitive Landscape and Key Companies:Key companies profiled in the cervical cancer treatment market report include F.Hoffmann-La Roche Ltd, Merck Sharp, Dohme Corp., GlaxoSmithKline plc., Genentech Inc., Amgen Inc., Advaxis Inc., Biocon, Allergan Inc., Pfizer Inc., and AstraZeneca. These companies are focused on expanding their product offerings to meet the growing global demand. Their international presence enables them to serve a wide customer base, thereby enhancing their market reach.